July 20, 2018 Update – Bayer discontinues the sale of Essure. More information found here.
Essure lawsuits are currently being filed against Bayer, the manufacturer of Essure, by women who have experienced life-altering injuries who claim that Bayer did not fully disclose the risk of injury from Essure, a non-surgical permanent birth control IUD. Although Essure has been removed from the market in many countries, it is still marketed to U.S. women.
The Truth in Essure?
According to Bayer, Essure is a “non-surgical” permanent birth control solution for women.
- Women who are implanted with Essure are 10 times more likely to need additional surgeries than women who get standard sterility surgery.
- Studies suggest that as many as 9.6% of women could become pregnant after an Essure implant – that is more than four times the estimated risk after a traditional sterility surgery.
- The truth is Bayer Figured Out How to Get the Device In… But they Never Figured Out How to Get it Out!
What is Essure?
Essure is a widely used medical device marketed as a permanent birth control for women ages 21 to 45. Approved by the U.S. Food and Drug Administration in 2002, Essure is a made of two nickel-titanium and stainless steel coils with a filler made of PET (polyethylene terephthalate) fibers.
It has been estimated that more than 1 million women in the U.S. have had the device implanted.
How Does it Work?
Essure is inserted in an OB-GYN’s office in ten minutes or less, according to Essure implant guidance. Removal is generally not discussed, and yet many women will experience complications leading to the removal of the Essure device.
One Essure coil is inserted through the vagina and cervix into each fallopian tube. Over the next several months, scar tissue forms around the coils, creating a barrier that blocks the tubes and keeps the eggs from being fertilized or making their way to the uterus, thus preventing conception.
Women implanted with Essure are required to return three months after the procedure for a follow-up X-ray utilizing dye to confirm that the tubes are fully blocked.
Removing the Essure Device has been a source of much frustration for women experiencing complications from the Essure device. There are very few doctors trained to remove the devices – Bayer has not trained doctors in removal. As more and more women seek removal, several OB-GYNs have emerged as specialists in Essure removal. Women seeking removal are often guided to these specialists through word of mouth and social media support groups.
Removal of the Essure device in tact is very important so that parts of the nickel and steel coils do not remain in the women’s body opening it up to future complications. To do this, the majority of women (75.2% according to a recent online survey of 564 women) require a hysterectomy, with an alarming 44% of these women requiring more than one surgery.
Essure Lawsuits Filed for Complications With Essure
Hundreds of Essure Lawsuits have been filed against Bayer Inc. (the manufacturer of Essure) by women who have experienced life changing complications.
Migration/Expulsion of Device
Women report migration of the Essure device outside the uterus and can the implant can get lodged in organs or the abdominal wall. Essure devices have also been found in the uterus.
Injuries resulting from migration of the Essure device vary – women have found the coils of the device in many different locations in their body, sometimes puncturing organs. Invasive hysterectomies have been required to remove these devices. Sometimes multiple surgeries are required to remove the devices.
Painful Symptoms / Constellation of Symptoms
Women describe many symptoms that have been explained by their doctors as their bodies learning to accept the coils – some women find the pain does go away but for many women, these symptoms continue and even increase.
Some women describe a constellation of symptoms while their body fights to reject the device in their body. These symptoms vary tremendously with the women and include bloating/weight gain, pain with sexual intercourse, incontinence, chronic pelvic pain and cramping, heavy periods and more.
Fetal Deaths Under-Reported
Congressman Mike Fitzpatrick recently revealed 303 fetal deaths caused by Essure, as opposed to the 5 deaths reported to the FDA.
According to a private analyst who combed through the FDA’s public database, the FDA may have greatly underestimated the number of fetal deaths among women who became pregnant after using Essure. The FDA reported a mere five fetal deaths while Madris Tomes, founder, and CEO of Device Events, noted there were 303 reports of fetal deaths tied to Essure as reported in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.
Women implanted with Essure have a higher percentage of Etopic pregnancies. An etopic pregnancy cannot support the life of a fetus for very long and risks the health of the mother if immediate care is not sought.
Women with Essure Devices have a higher percentage of Etopic pregnancies. Etopic pregnancies occur when fertilization of the egg happens outside of the uterus. Etopic pregnancies can’t proceed normally.
Originally, Conceptus warned women to test for Nickel Allergies prior to Essure implant. But, proudly had this warning and the required skin test removed from the label in 2011. Many women describe allergy-like reactions to Nickel that include hair loss, dental issues, weight gain, fatigue and more.
Essure is 55% nickel – Many women report side effects that may actually be reactions to nickel in their body. Reported side effects that may be an allergic reaction to nickel include hair loss, dental issues, weight gain, chronic fatigue, and more. The original Essure label required a skin test and warned of nickel allergies, this was removed in 2011.
Top Complications from Essure
- FEARS (FDA Adverse Event Reporting System) Analysis – They tell you about Adverse Events they know of, not whats REALLY happening to you!
- Bayer says about 1 million Essure devices have been sold worldwide. More women will be at risk for complications while the FDA continues to study this device.
|Original Labeled – 2002|
|1 out of 7 women would have improper placement and will require second placement procedure.|
|Mild to moderate pain||Overabsorption of fluid|
|Pelvic or back discomfort for a few days||Nausea and/or vomiting|
|Infection||Temporary changes in menstrual cycle|
|Essure device may be expelled from body||Broken Essure micro-insert|
|Labeled as “rare”|
|Essure device may be expelled from body||Broken Essure micro-insert|
A black box warning is the strictest warning put in the labeling of prescription drugs or drug products by the Food and Drug Administration (FDA) when there is reasonable evidence of an association of a serious hazard with the drug. The black box warning must be part of the physician and patient labeling materials and includes a statement noting the risks associated with the device.
Essure Black Box Warning
WARNING: Some patients implanted with the Essure System for Permanent Birth Control have reported adverse events, including perforation of the uterus and/or fallopian tubes, intra-abdominal or pelvic device migration, persistent pain, and allergy or hypersensitivity reactions. Some of these reported events resulted in device removal that required abdominal surgery. This information should be shared with patients considering sterilization with the Essure device during adiscussion of the benefits and risks of the device.
Essure Decision Checklist
In lieu of removing the device from the market, the FDA announced a new “decision checklist” that must be signed by a patient and doctor before implantable sterilization devices such as Essure can be implanted.
The checklist is supposed to list every significant adverse event and patient outcomes. It is also supposed to contain information related to the removal and/or reversal of the device. Each item in the checklist should be accompanied by a line for the patient to initial, acknowledging their understanding of the information.
Furthermore, the checklist should include a summary at the end of the document. This should be followed by signature lines for both the patient and physician. A copy of the Patient Decision Checklist will be given to the patient and a copy will also be provided to the patient.
What is a Patient Decision Checklist?
According to the FDA, a patient checklist highlights the key risk and benefit information and will be included at the endo of the patient-labeling brochure. The checklist is intended to be reviewed and signed by the patient and physician and should be printed in a fashion where it can be easily separated from the remainder of the patient information brochure.
A History of Problems for Bayer Results in Essure Lawsuits
Bayer AG was founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott. In 1925, Bayer became part of IG Farben, A German chemical company conglomerate that engaged in human experimentation on Auschwitz prisoners during World War II. After World War II, the allies broke the companies up and Bayer continued to operate as its own drug company.
Marketed as “Science for a Better Life” Bayer has been involved with a number of drugs and devices that have notably had legal issues.
Essure was initially manufactured by Conceptus, a company that began focusing on the design, development, and clinical testing of the permanent form of birth control in 1998. Essure had shown promise by eliminating the cutting, clipping, and burning associated with tubal ligation. After clinical testing, Conceptus began marketing Essure commercially in Australia, Singapore, Europe, and Canada.
Bayer acquired Conceptus Inc. for about $1.1 billion in 2013 to add a permanent contraception device (Essure) to complement the German company’s offerings in women’s health.
Essure Approved by FDA in 2002
When the U.S. Food and Drug Administration (FDA) approved Essure in 2002, the agency required the original manufacturer, Conceptus, to monitor the outcomes of women who were enrolled in the five-year clinical trial upon which the agency’s approval was based. The extended approval time was for an additional four years.
In a May 1, 2015 news release, Bayer released the post-market report on the safety, effectiveness, and tolerability of Essure, a report experts say is one-sided because it:
- Never mentions that nearly one-third of the women originally enrolled in the study dropped out for various reasons.
- Understates the levels of pelvic pain reported by women who did complete the study.
- Does not disclose that the study’s lead author is a paid consultant to Bayer.
Further, according to a Health News Review report, Conceptus failed to report the outcome of the five-year study and the results were submitted for publication a year after Bayer acquired the device.
Bayer continues to market Essure as one the most effective, affordable and convenient means of birth control – ideal for the busy 21st-century woman and mother. Company officials say it is sold in at least 23 countries, and at least one million devices are in use worldwide.
- The TRUth is, Women who are implanted with Essure are 10 times more likely to need new additional operations as women who get standard sterility surgery. And yet, Bayer continues to market their Essure implant as “non-surgical”.
- Bayer Profits From More than 8,000 Essure Implants Each Year While Injured E-Sisters Fight to Have the Device Removed From the Market
Essure Regulatory Timeline
Bayer introduced a pregnancy test, Primodos, that consisted of 2 pills that was later blamed for birth defects – it was removed from the market in the 1970’s.
Cutter’s Factor VII, hemophilia drug, was found to be the source of the high rate of hemophiliacs with AIDS (Cutter was purchased by Bayer in 1978)
52 deaths attributed to Bayer’s statin drug, Baycol. Baycol was discontinued in 2011.
Nov 04, 2002
Essure FDA approved as a Class III Medical Device
Safety Label Changes
Jul 01, 2011
Physician label updated to remove contraindication and to revise a warning regarding nickel sensitivity in physicians label
Bayer Purchases Conceptus
Jun 05, 2013
Bayer Group purchases 96.4% of Conceptus, Inc. for $1.1 billion. Conceptus owned Essure which had been used by more thatn 750,000 women around the globe by this time.
Safety Label Changes
Oct 20, 2013
FDA review of Essure – label updated to include risks of chronic pelvic pain and device migration
Sep 24, 2015
FDA holds a public meeting as a result of growing reports of complications.
Blackbox Warning & Checklist Required
FDA requires “black box” label warning about Essure's serious side effects, plus a checklist for doctors to discuss potential risks with patients